NeuroCog Trials, Inc. announces that the MATRICS Consensus Cognitive Battery (MCCB) has been chosen as the primary outcome measure by a large pharmaceutical company to evaluate their novel compound’s pro-cognitive potential among patients with schizophrenia in a multi-site clinical trial.
Richard Keefe, Ph.D., Founder and CEO of NeuroCog Trials, and a member of the MATRICS Neurocognition Committee, said, “I am pleased to see the MCCB utilized by the pharmaceutical industry for large, multi-site clinical trials. This is the next step that the MATRICS committee envisioned, and I fully expect the MCCB to demonstrate the same robust test-retest reliability, small practice effects, correlations with measures of functional capacity, practicality and tolerability as was displayed in our development of the battery.”
The forthcoming trial will assess several hundred patients at four different time points with the MCCB. Dr. Keefe added, “I continue to believe that the MCCB will become the predominant neurocognitive assessment battery in the clinical trials of schizophrenia, as well as other disorders of cognition.”